老年患者巴氯芬与替扎尼定的安全性:大型整合医疗系统回顾性队列研究
该研究在Kaiser Permanente南加州系统65至99岁人群中,比较巴氯芬、替扎尼定与环苯扎林相关的严重损伤事件。相比环苯扎林,巴氯芬复合损伤风险高69%(aHR 1.69,95%CI 1.51-1.88),替扎尼定高34%(aHR 1.34,95%CI 1.11-1.62)。作者认为结果支持将巴氯芬和替扎尼定与其他骨骼肌松弛剂一并列入Beers标准。
要点
- 相比环苯扎林,巴氯芬复合损伤风险高69%(aHR 1.69,95%CI 1.51-1.88)。
- 替扎尼定复合损伤风险较环苯扎林高34%(aHR 1.34,95%CI 1.11-1.62)。
- 巴氯芬与替扎尼定随时间推移的无损伤概率均低于环苯扎林。
核心结论
- 老年患者使用巴氯芬或替扎尼定相比环苯扎林与更高损伤风险相关,支持将其列入Beers标准。
研究设计与样本
- 共87,896名参与者,识别118,426次研究药物使用事件,采用ICD-9与ICD-10编码识别严重损伤事件并调整众多人口学与临床协变量。
主要发现
- 相比环苯扎林,巴氯芬复合损伤结局aHR 1.69(95%CI 1.51-1.88),替扎尼定aHR 1.34(95%CI 1.11-1.62)。
- 巴氯芬与替扎尼定相比环苯扎林随时间推移无损伤概率更低。
关键数值与推荐
- 严重损伤事件包括骨折、导致骨折的跌倒、脑损伤和脱位损伤。
- AGS 2023更新版Beers标准建议老年肌肉骨骼主诉者避免使用骨骼肌松弛剂,但巴氯芬与替扎尼定被排除在该条款之外。
临床怎么用
- 对老年肌肉骨骼主诉患者,处方巴氯芬或替扎尼定前应权衡其较环苯扎林更高的损伤风险。
- 本研究结果可为更新Beers标准、将巴氯芬与替扎尼定纳入潜在不适当用药提供依据。
局限性
- 回顾性设计,可能仍存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The AGS 2023 updated Beers Criteria for potentially inappropriate medication use in older adults recommends avoidance of skeletal muscle relaxants (SMRs) for musculoskeletal complaints. Two SMRs, baclofen and tizanidine, are excluded from this criterion. Clinicians may therefore consider baclofen or tizanidine as options for older adult patients with musculoskeletal complaints; however, evidence for this conclusion is lacking. PURPOSE: To investigate injury events associated with baclofen and tizanidine in older adults compared to cyclobenzaprine, an SMR included in the Beers Criteria. METHODS: We conducted a retrospective cohort study at Kaiser Permanente Southern California (KPSC) in patients age 65 to 99 years. Participants were identified as KPSC members dispensed a study SMR between January 1, 2008, and December 31, 2018. Serious injury events were identified in the electronic medical record using ICD-9 and ICD-10 codes for the following: fracture, fall leading to fracture, brain injury, and dislocation injury. Findings were adjusted for numerous demographic and clinical covariates. Secondary analyses investigated injury-free probabilities based on the type of injury event. RESULTS: From a population of 87,896 participants, 118,426 study medication episodes were identified. Compared with cyclobenzaprine, baclofen demonstrated a 69% greater risk (adjusted Hazard Ratio [aHR] 1.69, 95% Confidence Interval [CI] 1.51-1.88), and tizanidine carried a 34% greater risk (aHR 1.34, 95% CI 1.11-1.62) for composite injury outcomes. Both baclofen and tizanidine demonstrated lower injury-free probabilities over time when compared with cyclobenzaprine. CONCLUSIONS: Older adult patients dispensed baclofen or tizanidine were found to have an increased risk of injury when compared with cyclobenzaprine, currently included on the Beers Criteria. These findings support the inclusion of baclofen and tizanidine on the Beers Criteria along with other SMRs as potentially inappropriate medications in use in older adults with musculoskeletal complaints. Due to a retrospective design, the risk for residual confounding may remain.
引用
- George MM, Deamer RL, Lee-Rodriguez S, et al. Safety of Baclofen and Tizanidine in Older Adults: A Retrospective Cohort Study in a Large Integrated Health Care System. J Am Geriatr Soc. 2025. PMID: 40944832. doi:10.1111/jgs.70097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。